Tracking Medicare news, policy, and coverage changes.
The real question is whether we’re being honest with ourselves about what medical education was designed to produce, and whether our current system is still doing that job. The post Medical Education Is at a Crossroads. AI Isn’t the Problem — It’s the Mirror appeared first on MedCity News .
Read full article →The rise of metabolic gene therapies represents a critical juncture for benefits management. These treatments offer genuine hope for patients with serious conditions, but they also pose significant financial challenges. The post Preparing Benefits For the Next Wave: Gene Therapy Medications appeared first on MedCity News .
Read full article →By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results were encouraging.
Read full article →A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.
Read full article →Much-awaited results at ASCO show that scientists have indeed found a way to drug a "greasy ball" involved in pancreatic cancer.
Read full article →A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better treatments for one of the deadliest types of cancer.
Read full article →Kenya's Lake Turkana is the world's largest permanent desert lake. Its waters have long sustained hundreds of thousands. Now the lake is facing multiple threats — and threatening those who rely on it.
Read full article →NPR's Ayesha Rascoe speaks with former member of the U.S. Chemical Safety Board Rick Engler about the current state of chemical safety following a string of incidents in the U.S.
Read full article →A new drug for pancreatic cancer gives some hope for one of the most dire types of cancer.
Read full article →(MedPage Today) -- CHICAGO -- RASolute 302 trial results were hailed as a game-changing breakthrough in the treatment of pancreatic cancer. The phase III study showed that second-line daraxonrasib, an investigational oral RAS(ON) multi-selective...
Read full article →Sen. Bill Cassidy (R-La.) finds himself in a unique position: scorned by President Trump and out of the running for reelection, but still in charge of the highly influential Senate health committee, which can block nominees to head three health agencies currently without permanent leaders. The next few months could determine whether his legacy is restraining...
Read full article →ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.
Read full article →